Brief: Nabriva Therapeutics Expands Xenleta(Lefamulin) Presence With Exclusive Agreement With Er-Kim Pharmaceuticals
18/07/2022 12:02
July 18 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS EXPANDS XENLETA® (LEFAMULIN) PRESENCE
WITH
EXCLUSIVE AGREEMENT WITH ER-KIM PHARMACEUTICALS
* NABRIVA THERAPEUTICS PLC - ER-KIM GAINS EXCLUSIVE RIGHTS
TO
DISTRIBUTE XENLETA IN COUNTRIES LIKE BULGARIA, CROATIA, CZECHIA,
GREECE, HUNGARY, OTHERS
* NABRIVA THERAPEUTICS PLC - ER-KIM ALSO MAY DISTRIBUTE
XENLETA TO
AN ADDITIONAL FIVE COUNTRIES THROUGH A NAMED PATIENT USAGE (NPU)
PROGRAM
* NABRIVA THERAPEUTICS PLC - NABRIVA WILL BE EXCLUSIVE
SUPPLIER OF
XENLETA TO ER-KIM
Source text for Eikon: ID:nGNX6FYCfG
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update